A PRECISION T-CELL THERAPY STALLED HARD-TO-TREAT CANCERS IN 16 OF 27 PATIENTS.
A more precise signal gave exhausted treatment paths one more opening.
In the first human trial of invikafusp alfa, an experimental bispecific T-cell agonist, 59.3% of participants treated at the optimal dose had no disease progression. The patients had advanced, heavily pretreated solid tumors, many resistant to standard checkpoint immunotherapy.
WHAT HAPPENED
Researchers enrolled people with several kinds of advanced solid cancer, most of which had responded poorly to immune checkpoint blockade. Phase 1 tested different doses every two weeks; phase 2 used the dose where the intended immune effect peaked. Across both phases, 16 of 27 participants at that optimal dose had no progression, while four had reductions greater than 30% in targeted tumors. Two responders had metastatic colorectal cancers receiving the drug as seventh-line treatment, and another had stage 4 non-small-cell lung cancer. Flu-like side effects were expected and generally manageable. Participants at non-optimal doses did not appear to benefit significantly.
WHY THIS IS HOPESLOP
This is not a cure announcement. It is an early signal that immune activation can be made more selective: the treatment expanded the intended T-cell populations without broadly stimulating other T cells, and it showed activity in people with few remaining options. The sample is small and mixed, so larger controlled trials must determine whether the signal becomes durable clinical benefit.
ORIGINAL SOURCENIH / Nature MedicineRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.